Prognostic factors in pleuro-pulmonary blastoma

Pediatr Blood Cancer. 2007 Mar;48(3):318-23. doi: 10.1002/pbc.20842.

Abstract

Purpose: To evaluate the prognostic factors in a series of children affected by pleuropulmonary blastoma (PPB).

Patients and methods: Clinicopathological findings, treatment, and outcome of 22 PPB cases observed in 13 Italian Associations for Pediatric Hematology and Oncology centers are reported. Clinical data, surgical notes, pathologic findings, and summaries of treatment were taken from the charts and correlated with outcome by standard statistical methods.

Results: The series included 22 patients (14 males) with a median age of 30.5 months followed up for a median of 22 months (range 2-176 months). In nine patients the PPB developed with lung involvement only. Congenital lung cysts were recorded in five cases. Nine patients had recurrences. Gender, side, tumor size, pre-existing lung cysts, and extent of surgical resection at diagnosis did not significantly affect survival by univariate analysis. Achieving total resection of the tumor at any time of treatment resulted in a significantly better prognosis (P = 0.01), whereas extrapulmonary involvement at diagnosis resulted in a significantly worse prognosis (P = 0.01). Estimated 15-year event-free and overall survival rates were 44 and 49% for all patients, respectively.

Conclusions: PPB is an aggressive neoplasm. Total resection of PPB performed at any time of treatment appears to provide a better outcome, whereas extrapulmonary involvement at diagnosis worsens the prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Dactinomycin / administration & dosage
  • Disease Progression
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Epirubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Ifosfamide / administration & dosage
  • Infant
  • Kaplan-Meier Estimate
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / surgery
  • Male
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Pleural Neoplasms / drug therapy
  • Pleural Neoplasms / mortality*
  • Pleural Neoplasms / pathology
  • Pleural Neoplasms / radiotherapy
  • Pleural Neoplasms / surgery
  • Pneumonectomy
  • Prognosis
  • Pulmonary Blastoma / drug therapy
  • Pulmonary Blastoma / mortality*
  • Pulmonary Blastoma / pathology
  • Pulmonary Blastoma / radiotherapy
  • Pulmonary Blastoma / surgery
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Risk Factors
  • Second-Look Surgery
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Dactinomycin
  • Epirubicin
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Carboplatin
  • Ifosfamide

Supplementary concepts

  • VAIA protocol